Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy ofOxford BioDynamics' EpiSwitch blood-based Colorectal No-Stool Test (NST) High ...

OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company, has announced the successful outcomes of a clinical study for its EpiSwitch® Colorectal No-Stool Test (NST), which has been ...

A new blood test was found to detect colon cancer with more than 80% accuracy — and to rule it out for 90% of healthy people.

Hereditary cancer risk can be passed down among generations, just like physical characteristics that we can identify in our ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...